每经AI快讯，西安市人民政府办公厅近日印发《促进生物医药产业能力提升实施方案(2025—2027 年)》。其中提出，打造中药产业链群。壮大"中药材种植—中成药生产—品牌建设"中药产业链群。鼓 励周至县等地建设中药材生产基地，恢复万寿路国家级中药材专业市场功能，支持建设交易中心线上平 台，保障中药材可持续发展和连续供应，补足上游中药材种植短板。支持企业培育一批过亿元中药大品 种，持续在生产领域扩大产能。加大经典名方、验方及中药新药研发力度，支持中药大品种二次开发和 院内制剂转化，做大做强"秦药"品牌。到2027年，全市中药链群产业规模力争达到90亿元。 ...

行业研究丨深度报告丨医疗保健 [Table_Title] 复苏中前行，聚焦出海、创新——非药行业 2026 年度投资策略 %% %% %% %% research.95579.com 1 丨证券研究报告丨 报告要点 [Table_Summary] 突破量价限制，出海、创新成为关键。2025 年非药板块业绩持续承压，集采降价、医保控费， 零售药店关店优化、非必需医疗需求尚未恢复，行业面临量价限制，但仍然有公司通过出海、 创新等关键抓手实现戴维斯双击。展望 2026 年，我们认为胰岛素出海、医疗器械出海、中药 的创新转型、创新器械等仍会创造个股α机会。 分析师及联系人 [Table_Author] SFC：BUZ392 请阅读最后评级说明和重要声明 2 / 32 %% %% %% %% research.95579.com 2 彭英骐 徐晓欣 张楠 SAC：S0490524030005 SAC：S0490522120001 SAC：S0490524070006 医疗保健 cjzqdt11111 [Table_Title 复苏中前行，聚焦出海、创新——非药行业 2] 2026 年度投资策略 [Table_Summa ...

| 36 | 青岛北琪实业有限公司 | | --- | --- | | 37 | 青岛北洋建筑设计有限公司 | | 38 | 青岛贝来文化科技有限公司 | | 3a | 青岛波尼亚食品集团有限公司 | | 40 | 青岛琛蓝健康产业集团有限公司 | | 41 | 青岛瓷兴新材料有限公司 | | 42 | 青岛达能环保设备股份有限公司 | | 43 | 青岛大东自动化科技有限公司 | | 44 | 青岛大牧人机械股份有限公司 | | 45 | 青岛德才高科新材料有限公司 | | 46 | 青岛德固特节能装备股份有限公司 | | 47 | 青岛德盛机械制造有限公司 | | 48 | 青岛点石文具用品有限公司 | | də | 青岛鼎信通讯股份有限公司 | | 50 | 青岛东方铁塔股份有限公司 | | 51 | 青岛方天科技股份有限公司 | 近日，青岛市民营经济发展局正式公布2025年度青岛市民营领军标杆企业名单，琛蓝健康产业集团凭借 其在健康产品研发领域的卓越创新成果和全面的产业布局，成功入选"2025年度青岛市民营领军标杆企 业"。 此次获奖是继琛蓝健康获得"青岛市海洋高成长性企业""山东省瞪羚企业""科创中 ...

Core Viewpoint - The newly approved "Zhengzhou Traditional Chinese Medicine Development Promotion Regulations" aims to enhance the development of traditional Chinese medicine (TCM) in Zhengzhou, focusing on service, industry growth, talent cultivation, and cultural inheritance, with implementation starting on March 1, 2026 [1][2]. Group 1: Service and Management - The regulations integrate TCM development into national economic and social planning, establishing a service and management system that aligns with TCM development principles [2]. - A cultural promotion week for TCM will be established annually, fostering a societal atmosphere that values and utilizes TCM [2]. - Support for the construction of national TCM medical centers and the establishment of TCM clinics in community health service centers and township hospitals is emphasized [2][3]. Group 2: Industry Support - A collaborative mechanism for TCM industry development will be established, covering the entire industry chain from cultivation to production [4]. - The regulations encourage the development of new TCM drugs and the use of modern technology in traditional medicine production, aiming to enhance quality and efficacy [4]. - The establishment of smart shared TCM pharmacies utilizing modern information technology is promoted to improve service delivery [4]. Group 3: Talent Development - A talent strategy for TCM will be implemented, focusing on the cultivation and incentive mechanisms tailored to TCM characteristics [5][6]. - The regulations support the introduction of high-level TCM talents, including academicians and renowned practitioners, to enhance the expertise within the field [6]. - Emphasis is placed on the development of intelligent devices for TCM practices, alongside the establishment of academic inheritance systems to promote traditional knowledge and skills [6].

人民财讯11月24日电，上海市人民政府办公厅印发《上海市全面深化药品医疗器械监管改革促进医药产 业高质量发展的若干措施》，其中提出，支持中药研发创新。建立医疗机构规范收集整理人用经验数据 机制，探索人用经验数据作为真实世界证据用于药品注册申报。制订医疗机构应用传统工艺配制中药制 剂备案管理规定。支持疗效确切、特色优势明显的医疗机构中药制剂及名老中医方开发转化为中药新 药。鼓励医疗机构、研发单位和药品企业共同打造中药创新与产业转化平台，支持中药创新药临床研究 和古代经典名方中药复方制剂研究，鼓励中药大品种培育和经典品种二次开发。外省市按照国家药品标 准生产的中药配方颗粒在我市销售的，免予备案。 ...

为促进科技与产业有效衔接，活动还发布了7家重点企业的技术需求以及11项融资需求，总资金需 求规模达数亿元，涉及新药研发、生产线扩建、临床申报等多个环节。两家企业代表在现场路演中分享 了企业在技术创新与产业升级方面的迫切诉求。同时，两家金融投资机构介绍了针对生物医药企业的政 策性金融工具与市场化投资方案，推动科技成果从实验室走向产业化。现场交流活跃，初步达成合作意 向10项，为广西生物医药产业高质量发展注入新动能。（梁菁惠） 活动现场集中展示了34项技术成果，覆盖中药新药、院内制剂转化、医疗器械、化学创新药等多个 前沿领域。来自广西中医药大学、广西医科大学第一附属医院、玉林市中西医结合骨科医院等单位的8 个技术成果团队进行了现场路演，充分展现了广西在药品与医疗器械创新方面的扎实基础与科研实力。 近日，以"产学研用金协同 共筑产业新生态"为主题的广西生物医药产业"产学研用金"对接活动在 广西中医药大学举办。此次活动是广西首次聚焦生物医药领域创新成果与生产企业精准对接的专项活 动，旨在推动产业链、创新链、资金链与人才链深度融合，将本地资源优势切实转化为产业发展优势。 ...

Core Viewpoint - The key to enhancing the sense of health among the public lies in promoting the coordinated development and governance of the "three medicines" (medical services, medical insurance, and pharmaceuticals) [1] Group 1: Medical Services - The shift in focus from "disease-centered" to "health-centered" medical services is crucial for high-quality development in the health sector [2] - As of now, 338 cities in China have achieved mutual recognition of medical examination results, with over 200 items recognized [2] - The construction of tightly-knit urban medical groups and county-level medical communities is accelerating, with a projected 36 million two-way referrals by 2024, a 46% increase from 2020 [2] - There is still room for improvement in graded diagnosis and treatment, integration of medical and preventive care, and continuity of services [2] Group 2: Medical Insurance - China has established the world's largest medical insurance network, with annual fund expenditures nearing 3 trillion yuan [4] - The payment method has transitioned from "fee-for-service" to "disease-based payment," achieving a coverage rate of 95% for disease types [4] - By 2024, 96% of designated grassroots medical institutions will be included, and 97% of administrative villages will have access to medical insurance services [4] - A pilot program for disease-based payment for 57 types of traditional Chinese medicine (TCM) is set to launch [4] Group 3: Pharmaceuticals - The drug safety inspection pass rate has improved from 97.9% in 2017 to 99.4% in 2024, indicating a stable overall drug safety situation [6] - The number of new drugs under research in China has reached 1,250, accounting for about 30% of the global total [7] - In the first half of 2025, the total value of innovative drug licensing transactions reached 66 billion USD, establishing China as a significant source of global drug innovation [7] - The approval of new drugs and innovative medical devices has seen significant growth, with increases of 59% and 87% respectively [7]

Core Insights - The National Medical Products Administration (NMPA) has approved 204 innovative drugs and 265 innovative medical devices since the beginning of the 14th Five-Year Plan, with 50 innovative drugs and 49 innovative medical devices approved in the first seven months of this year [1][2] - China's pharmaceutical industry ranks second globally, with approximately 30% of innovative drugs under research worldwide [1][2] Group 1: Drug Safety and Regulation - The NMPA emphasizes the importance of drug quality and safety, implementing dynamic supervision throughout the drug lifecycle and establishing a risk consultation mechanism [1] - Special actions have been taken to enhance drug safety, including annual sampling of over 200,000 batches of various drugs and 20,000 batches of medical devices [1] Group 2: Support for Pharmaceutical Development - The NMPA has reformed the review and approval system, introducing four expedited channels for breakthrough therapies and prioritizing certain products for faster approval [2] - The approval of traditional Chinese medicine (TCM) has also increased, with 27 innovative TCM drugs approved during the 14th Five-Year Plan [2] Group 3: Meeting Public Health Needs - The NMPA has optimized the review process for urgently needed foreign drugs, allowing patients to access the latest global drug developments more quickly [2] - A total of 387 pediatric drugs and 147 rare disease drugs have been approved since the start of the 14th Five-Year Plan, addressing the needs of key populations [2]

Core Insights - Shanghai Agricultural Science and Technology Innovation Valley has achieved significant progress in its first year, with total investments exceeding 20 billion yuan, focusing on future industries such as plant extraction [1][2] - The establishment of the Yangtze River Delta Traditional Chinese Medicine Concept Verification and Achievement Transformation Center aims to enhance the conversion of TCM research into market-ready products, supported by national resources and partnerships with leading pharmaceutical companies [1] - The launch of the Shanghai Agricultural Science and Technology Innovation Valley Joint Innovation Center promotes the integration of academia, industry, and research, attracting new enterprises in smart equipment, biotechnology, and digital agriculture [2] Investment and Development - Total investment in the Shanghai Agricultural Science and Technology Innovation Valley has surpassed 20 billion yuan, indicating strong financial backing for agricultural innovation [1] - The initiative includes 31 major projects in plant extraction and aims to streamline the entire process from research and development to industrialization [1] Strategic Initiatives - The center will implement a dual support mechanism combining "verification assessment + resource integration" to facilitate the development of new TCM drugs and food products [1] - The "Four Batch" project aims to establish significant technological infrastructure, publish technology lists, form industry innovation coalitions, and launch high-value plant extraction products [2]

Core Insights - The 2025 Fortune Global 500 list features 130 Chinese companies, with an increase of one company from the previous year, highlighting the growing presence of Chinese enterprises on the global stage [1][5]. Group 1: Overall Rankings and Financial Performance - The total revenue of the companies on the Fortune Global 500 list is approximately $41.7 trillion, accounting for over one-third of the global GDP, with a year-on-year growth of about 1.8% [2]. - The average profit of the 130 Chinese companies listed increased by 7.4% year-on-year, rising from $39 billion to $42 billion [4]. - The total net profit of all listed companies grew by approximately 0.4% year-on-year, totaling around $2.98 trillion [2]. Group 2: Notable Companies and Rankings - Walmart retains its position as the largest company globally for the twelfth consecutive year, followed by Amazon and China's State Grid Corporation in third place [3]. - The China Industrial Bank is the only Chinese company in the top ten of the profit rankings, with profits exceeding $50.8 billion last year [3]. - Guangdong province has 18 companies on the list, with six headquartered in Guangzhou, including notable firms like GAC Group and Guangzhou Pharmaceutical Holdings [5][6]. Group 3: Company-Specific Highlights - GAC Group achieved a vehicle production and sales volume of 1.9166 million and 2.0031 million units, respectively, with a significant increase in overseas sales by 67.6% [6]. - Guangzhou Industrial Investment Holdings ranked 406th globally, marking its third consecutive year on the list, and has made significant strides in the Chinese 500 list, ranking 97th [6][7]. - Guangzhou Pharmaceutical Holdings ranked 459th and is the only Chinese company in the pharmaceutical sector to be listed, with a strong focus on research and development, holding over 200 ongoing projects [7].